Progress in the development of alternative pharmaceutical formulations of taxanes

B Nuijen, M Bouma, JHM Schellens… - Investigational new drugs, 2001 - Springer
The currently available taxanes paclitaxel(TaxolŽ) and docetaxel(TaxotereŽ) are clinically
effectiveagainst advanced breast, ovarian andnon-small cell lung cancer. Due to theirlow …

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A

M Bouma, B Nuijen, MT Jansen, G Sava… - International journal of …, 2002 - Elsevier
NAMI-A is a novel ruthenium complex with selective activity against cancer metastases currently
in Phase I clinical trials in The Netherlands. The chemical stability of this new agent was …

The role of afferents to the ventral tegmental area in the handling stress-induced increase in the release of dopamine in the medial prefrontal cortex: a dual-probe …

P Enrico, M Bouma, JB De Vries, BHC Westerink - Brain research, 1998 - Elsevier
This study was aimed to identify the neuronal pathways that mediate the handling stress
induced increase in the release of dopamine in the medial prefrontal cortex (mPFC) of the rat …

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A

M Bouma, B Nuijen, MT Jansen, G Sava… - … of pharmaceutical and …, 2003 - Elsevier
Imidazolium trans-tetrachloro(dimethylsulfoxide)imidazoleruthenium(III) (NAMI-A) is a novel
ruthenium complex with selective activity against metastases currently in Phase I clinical …

Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential

M Bouma, B Nuijen, DR Stewart, JR Rice… - Anti-cancer …, 2002 - journals.lww.com
AP 5280 is a novel polymer-conjugated platinum anticancer agent currently undergoing
phase I clinical trials. It is pharmaceutically formulated as a lyophilized product containing 200 …

Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A

M Bouma, B Nuijen, MT Jansen, G Sava, A Bult… - … of pharmaceutical and …, 2002 - Elsevier
NAMI-A is a novel ruthenium complex with selective activity against metastases currently in
Phase I clinical trials in The Netherlands. The photostability of this new agent in solid state …

Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A

M Bouma, B Nuijen, G Sava, A Perbellini… - International journal of …, 2002 - Elsevier
This paper describes the development of a stable pharmaceutical dosage form for NAMI-A,
a novel antimetastatic ruthenium complex, for Phase I testing. NAMI-A drug substance was …

Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices

B Nuijen, M Bouma, C Manada, JM Jimeno… - Investigational new …, 2001 - Springer
Kahalalide F is a novel marine-derivedantitumor agent isolated from the marinemollusk
Elysia rufescens, an organismliving in the seas near Hawaii. Thecompound has shown highly …

Case report: Salicylate intoxication can present with a normal anion gap metabolic acidosis depending on method used for measuring chloride

…, M Kwant, MD Themmen, M Bouma… - British Journal of …, 2022 - Wiley Online Library
Severe salicylate intoxication usually presents with a high anion gap metabolic acidosis.
We describe a patient with severe salicylate intoxication who presented with a surprisingly …

[PDF][PDF] Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280

M Bouma, B Nuijen, DR Stewart… - PDA Journal of …, 2003 - researchgate.net
AP 5280 is a novel polymer-conjugated platinum anticancer agent currently in Phase I
clinical trials. In order to guarantee the quality of AP 5280 drug substance for use in the …